Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- BGIN +4.4%, SHMD +4.4%, VZ +3.8%, CPAC +2.8%, GROY +1.5%, DEA +1.1%
Other news:
- SGMT +28.3% (prioritizes acne program, plans Phase 3 trial in 2H26; announces the pricing of an underwritten offering of 29,166,700 shares of its Series A common stock at a price of $6.00/share)
- MANE +19.4% (oral VDPHL01 achieved early, consistent, and robust hair growth in positive Phase 2/3 ‘302' clinical trial in male pattern hair loss; Conference call and webcast scheduled for 8:00 a.m. ET today)
- ORKA +16.9% (reports week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis; Management to host a conference call today at 8:00 a.m. ET)
- OGN +16.6% (to be acquired by Sun Pharma for $14 per share in cash)
- LEE +10.4% (names Nathan Bekke as CEO and Josh Rinehults as CFO)
- NTLA +7.1% (topline results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema)
- MRT +5.2% (authorizes $2.5 mln share repurchase program)
- LGND +4.6% (XOMA Royalty Corporation confirms it will be acquired by Ligand Pharmaceuticals (LGND) for $39.00/share; LGND raises FY26 guidance)
- WRD +2.8% (targets global AV rollout with Lenovo (LNVGY) partnership)
- NINE +2.7% (announces that Guy Sirkes notified the company of his decision to resign from his role as Executive Vice President and Chief Financial Officer in order to accept a position at another company)
- ADGM +2.6% (announces pivotal results for vCLAS Ventricular Ablation System)
- PLSE +2.2% (presents positive outcomes in late-breaking updated data from nPulse Cardiac Catheter System at Heart Rhythm 2026)
- PONY +2% (unveils new autonomous driving compute platform with Nvidia)
- XOMA +1.6% (XOMA Royalty Corporation confirms it will be acquired by Ligand Pharmaceuticals (LGND) for $39.00/share; LGND raises FY26 guidance)